Watchful waiting or watchful progression?

Prostate specific antigen doubling time (PSAdt) is a dynamic model of prostate tumor biology. It predicts aggressive disease and subsequent clinical recurrence after radical treatment. However, as yet there is only limited evidence for its validity in the watchful waiting population.

[1]  K. Kawabe,et al.  bcl‐2 Expression in Prostate Cancer and its Relationship to Cell Cycle and Prognosis , 1996 .

[2]  B. Baldetorp,et al.  Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. , 1996, Urology.

[3]  A. Hanlon,et al.  Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. , 1996, International journal of radiation oncology, biology, physics.

[4]  A. Pollack,et al.  Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. , 1994, Urology.

[5]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[6]  A. D'Amico,et al.  Linear regressive analysis using prostate‐specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer , 1993, Cancer.

[7]  T. Schultheiss,et al.  Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. , 1993, International journal of radiation oncology, biology, physics.

[8]  R. Sadasivan,et al.  Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. , 1993, The Journal of urology.

[9]  T. Stamey,et al.  Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.

[10]  L. Holmberg,et al.  High 10-year survival rate in patients with early, untreated prostatic cancer. , 1992, JAMA.

[11]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[12]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[13]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[14]  T. Stamey,et al.  Morphometric and clinical studies on 68 consecutive radical prostatectomies. , 1988, The Journal of urology.

[15]  D E Johnson,et al.  Histologic grading study of prostate adenocarcinoma: The development of a new system and comparison with other methods—A preliminary study , 1982, Cancer.

[16]  T. Schultheiss,et al.  Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. , 1995, International journal of radiation oncology, biology, physics.

[17]  G. Zagars.  Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. , 1992, International journal of radiation oncology, biology, physics.